Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
44
INTS Quote, Financials, Valuation and Earnings
Last price:
$0.51
Seasonality move
:
-9.18%
Day range:
$0.48 - $0.53
52-week range:
$0.19 - $3.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.24x
Volume:
8.4M
Avg. volume:
59.5M
1-year change:
-79.6%
Market cap:
$30.6M
Revenue:
--
EPS (TTM):
-$0.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics, Inc.
|
-- | -$0.06 | -- | -77.01% | $2.92 |
|
HBIO
Harvard Bioscience, Inc.
|
$20M | $0.01 | -5.93% | 8650% | $2.00 |
|
MBRX
Moleculin Biotech, Inc.
|
-- | -- | -- | -- | $6.67 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics, Inc.
|
$0.51 | $2.92 | $30.6M | -- | $0.00 | 0% | -- |
|
HBIO
Harvard Bioscience, Inc.
|
$0.76 | $2.00 | $33.8M | -- | $0.00 | 0% | 0.38x |
|
MBRX
Moleculin Biotech, Inc.
|
$7.24 | $6.67 | $15M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INTS
Intensity Therapeutics, Inc.
|
1.61% | 3.280 | 0.99% | 3.11x |
|
HBIO
Harvard Bioscience, Inc.
|
75.26% | 4.098 | 218.87% | 0.35x |
|
MBRX
Moleculin Biotech, Inc.
|
-1.47% | 1.294 | 1.49% | 1.18x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INTS
Intensity Therapeutics, Inc.
|
-$6K | -$2.7M | -364.61% | -380.13% | -- | -$2.4M |
|
HBIO
Harvard Bioscience, Inc.
|
$11.2M | $245K | -68.29% | -155.33% | 1.19% | $482K |
|
MBRX
Moleculin Biotech, Inc.
|
-$21K | -$5.9M | -502.35% | -552.21% | -- | -$7.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Intensity Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns INTS or HBIO?
Harvard Bioscience, Inc. has a net margin of -- compared to Intensity Therapeutics, Inc.'s net margin of -5.98%. Intensity Therapeutics, Inc.'s return on equity of -380.13% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics, Inc.-- -$0.06 $7.3M HBIOHarvard Bioscience, Inc.54.23% -$0.03 $56.9M -
What do Analysts Say About INTS or HBIO?
Intensity Therapeutics, Inc. has a consensus price target of $2.92, signalling upside risk potential of 471.9%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 163.96%. Given that Intensity Therapeutics, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Intensity Therapeutics, Inc. is more attractive than Harvard Bioscience, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics, Inc.5 1 0 HBIOHarvard Bioscience, Inc.1 1 0 -
Is INTS or HBIO More Risky?
Intensity Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.
-
Which is a Better Dividend Stock INTS or HBIO?
Intensity Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or HBIO?
Intensity Therapeutics, Inc. quarterly revenues are --, which are smaller than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Intensity Therapeutics, Inc.'s net income of -$2.7M is lower than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Intensity Therapeutics, Inc.'s price-to-earnings ratio is -- while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics, Inc. is -- versus 0.38x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics, Inc.-- -- -- -$2.7M HBIOHarvard Bioscience, Inc.0.38x -- $20.6M -$1.2M
-
Which has Higher Returns INTS or MBRX?
Moleculin Biotech, Inc. has a net margin of -- compared to Intensity Therapeutics, Inc.'s net margin of --. Intensity Therapeutics, Inc.'s return on equity of -380.13% beat Moleculin Biotech, Inc.'s return on equity of -552.21%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics, Inc.-- -$0.06 $7.3M MBRXMoleculin Biotech, Inc.-- -$17.02 -$26.5M -
What do Analysts Say About INTS or MBRX?
Intensity Therapeutics, Inc. has a consensus price target of $2.92, signalling upside risk potential of 471.9%. On the other hand Moleculin Biotech, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 2202.03%. Given that Moleculin Biotech, Inc. has higher upside potential than Intensity Therapeutics, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than Intensity Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics, Inc.5 1 0 MBRXMoleculin Biotech, Inc.2 0 0 -
Is INTS or MBRX More Risky?
Intensity Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moleculin Biotech, Inc. has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.192%.
-
Which is a Better Dividend Stock INTS or MBRX?
Intensity Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics, Inc. pays -- of its earnings as a dividend. Moleculin Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or MBRX?
Intensity Therapeutics, Inc. quarterly revenues are --, which are smaller than Moleculin Biotech, Inc. quarterly revenues of --. Intensity Therapeutics, Inc.'s net income of -$2.7M is higher than Moleculin Biotech, Inc.'s net income of -$25.4M. Notably, Intensity Therapeutics, Inc.'s price-to-earnings ratio is -- while Moleculin Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics, Inc. is -- versus -- for Moleculin Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics, Inc.-- -- -- -$2.7M MBRXMoleculin Biotech, Inc.-- -- -- -$25.4M
-
Which has Higher Returns INTS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Intensity Therapeutics, Inc.'s net margin of -255.85%. Intensity Therapeutics, Inc.'s return on equity of -380.13% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics, Inc.-- -$0.06 $7.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About INTS or NBY?
Intensity Therapeutics, Inc. has a consensus price target of $2.92, signalling upside risk potential of 471.9%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Intensity Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Intensity Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics, Inc.5 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is INTS or NBY More Risky?
Intensity Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock INTS or NBY?
Intensity Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Intensity Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or NBY?
Intensity Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Intensity Therapeutics, Inc.'s net income of -$2.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Intensity Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics, Inc.-- -- -- -$2.7M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns INTS or PTN?
Palatin Technologies has a net margin of -- compared to Intensity Therapeutics, Inc.'s net margin of --. Intensity Therapeutics, Inc.'s return on equity of -380.13% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics, Inc.-- -$0.06 $7.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About INTS or PTN?
Intensity Therapeutics, Inc. has a consensus price target of $2.92, signalling upside risk potential of 471.9%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Intensity Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Intensity Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics, Inc.5 1 0 PTNPalatin Technologies0 0 0 -
Is INTS or PTN More Risky?
Intensity Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock INTS or PTN?
Intensity Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or PTN?
Intensity Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Intensity Therapeutics, Inc.'s net income of -$2.7M is higher than Palatin Technologies's net income of --. Notably, Intensity Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics, Inc.-- -- -- -$2.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns INTS or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Intensity Therapeutics, Inc.'s net margin of --. Intensity Therapeutics, Inc.'s return on equity of -380.13% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital INTSIntensity Therapeutics, Inc.-- -$0.06 $7.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About INTS or TOVX?
Intensity Therapeutics, Inc. has a consensus price target of $2.92, signalling upside risk potential of 471.9%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Intensity Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Intensity Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INTSIntensity Therapeutics, Inc.5 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is INTS or TOVX More Risky?
Intensity Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock INTS or TOVX?
Intensity Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intensity Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INTS or TOVX?
Intensity Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Intensity Therapeutics, Inc.'s net income of -$2.7M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Intensity Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intensity Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INTSIntensity Therapeutics, Inc.-- -- -- -$2.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.66% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.94% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 4.41% over the past day.
